 fusions continued to achieve favorable responses with larotrectinib (Vitrakvi) according to data from an extended analysis of the phase 2 NAVIGATE (NCT02576431) trial and phase 1 LOXO-TRK-14001 trial (NCT02122913), presented at the 2022 World Conference on Lung Cancer.

Investigators observed an objective response rate (ORR) of 83% (95% CI, 61%-95%) in 23 evaluable patients with 

 fusion–positive disease. The 24-month progression-free survival (PFS) rate was 67% (95% CI, 44%-90%) while the 24-month overall survival (OS) rate was 72% (95% CI, 48%-97%).

“Larotrectinib demonstrated rapid and durable responses, extended survival, and a favorable long-term safety profile in patients with advanced lung cancer harboring 

 gene fusions,” the investigators stated in their poster.

NAVIGATE (NCT02576431) trial and LOXO-TRK-14001 enrolled patients with fusions in the 

 genes. Patients with cancer types including lung, thyroid, salivary, and colorectal cancers were enrolled on these trials, but this analysis included only those with advanced lung cancer. Both trials administered larotrectinib at a dose of 100 mg twice daily. The primary end point was ORR.

Larotrectinib was also investigated as an NTRK inhibitor in the SCOUT trial (NCT02637687). Across all 3 trials and disease types, this drug exhibited an overall response rate of 75% (95% CI, 61%-85%) by independent review committee (IRC) and 80% by investigator assessment (INV) in 55 patients with predominantly grade 1 adverse events (AEs).

 In 2018, based on SCOUT, NAVIGATE, and LOXO-TRK-14001, it was approved by the FDA for all solid tumors harboring an 

 fusion in adults and children with metastatic disease or those who cannot receive surgery and have no satisfactory alternative treatments.

At the previous data cutoff of July 20, 2020, 15 patients with advanced lung cancer were evaluated, with an ORR of 87% as assessed by an IRC and 73% by INV.

 With an additional year of follow-up, the ORR was still 87% by IRC, termed Group 1 in this analysis.

 They also presented data for Group 2, which consisted of these 15 plus an additional 11 patients. Both groups were evaluated at a data cutoff of July 20, 2021.

For Group 1, the median DOR was not reached; the median PFS was 33.0 months; and median OS was 40.7 months at a median follow-up of 24.0, 35.8, and 35.8 months, respectively.

Investigators found that of the 23 evaluable patients in Group 2, there were 2 complete responses, 17 partial responses (PR), and 4 patients with stable disease (SD). No patients had progressive disease. The median PFS and DOR in all 26 patients were not reached, while the median OS was 40.7 months (95% CI, 19.4–not estimable [NE]). The 24-month rate of DOR was 72%. The median follow-up for DOR was 12.9 months, while for PFS it was 14.6 months and for OS it was 12.9 months.

When including all 26 patients, the median age was 51.5 years (range, 25.0-76.0). Patients had received a median of 2 prior therapies (range, 0-6), with 46% having received 3 or more prior therapies.

Ten evaluable patients had baseline central nervous system metastases. They had an ORR of 80% (95% CI, 44%-97%) including 8 PRs and 2 with SD. For these patients, the median DOR was 9.5 months (95% CI, 3.6–NE), while the median PFS was 9.9 months (95% CI, 5.3–NE), and the median OS was 19.4 months (95% CI, 7.6–NE) at a median follow-up of 9.3, 11.0, and 12.0 months, respectively.

There were no new safety signals for Group 1, which previously reported mainly grade 1 and 2 AEs. Group 2 also reported mainly grade 1 and 2 treatment-related AEs. The most common treatment-related AEs included elevated alanine aminotransferase and aspartate aminotransferase (AST) levels (38.5% and 30.8%, respectively), followed by myalgia (26.9%) and constipation (23.1%). The most common grade 3 or higher AEs related to larotrectinib were increased AST (7.7%) and weight gain (7.7%). No patients discontinued treatment due to AEs.

These results confirm the long-term response and efficacy of larotrectinib in patients with advanced lung cancer who are identified as harboring 

 fusions. “These results support testing for 

 gene fusions in patients with lung cancer,” the investigators concluded in their poster.

1. Moreno V, Lin JJ, Tan DSW, et al. Extended follow-up of efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. Presented at: IASLC 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria. Abstract EP08.020-148.

2. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. doi:10.1056/NEJMoa1714448

3. FDA approves larotrectinib for solid tumors with NTRK gene fusions. FDA. December 14, 2018. Accessed August 4, 2022. https://bit.ly/3Sve4AX

4. Drilon A, Tan DSW, Lassen UN, et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers. JCO Precis Oncol. 2022;6:e2100418. doi:10.1200/PO.21.00418

Articles

Extended follow-up data from 2 trials confirmed that larotrectinib yielded positive progression-free and overall survival outcomes for patients with NTRK-positive lung cancer.

Larotrectinib Holds Ground as Effective Treatment in NTRK-Positive Lung Cancer

Patients with non–small cell lung cancer (NSCLC) harboring an 

mutation demonstrated encouraging responses to a novel regimen of amivantamab-vmjw (Rybrevant) in combination with lazertinib (Leclaza) plus carboplatin and pemetrexed, according to findings from the phase 1 CHRYSALIS-2 trial (NCT04077463).

In data presented at the 2022 IASLC World Conference on Lung Cancer, investigators noted that patients derived benefit from treatment irrespective of brain metastasis.

Among all patients (N = 20), the objective response rate (ORR) was 50% (95% CI, 27%-73%) with a clinical benefit rate (CBR) of 80% (95% CI, 56%-94%). In patients with baseline brain metastases (n = 10), the ORR was 50% (95% CI, 19%-81%) and the CBR was 80% (95% CI, 44%-98%).

Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity. Lazertinib is a highly selective, brain-penetrant, third-generation EGFR TKI with efficacy in activating 

 mutations, T790M, and central nervous system disease. The study authors explained in the presentation that combining platinum-based chemotherapy with targeted inhibition of EGFR-MET signaling may lead to improved outcomes.

Patients received 240 mg of lazertinib once daily, plus 1400 mg or 1750 mg of amivantamab on days 1, 2, 8, and 15 of cycle 1; day 1 of cycle 2, and 1750 mg or 2100 mg in cycle 3, followed by every 3-week dosing intervals thereafter. Patients also received 500 mg/m2 of pemetrexed and carboplatin at an area under the curve of 5, which was stopped after 4 cycles. The dosing for amivantamab was dependent on weight of less than 80 kg or 80 kg and above.

The primary end point was safety. Other end points included ORR, duration of response (DOR), CBR, progression-free survival (PFS), and overall survival (OS).

-mutated NSCLC who had received up to 3 prior lines of therapy with a TKI. The median patient age was 61 years (range, 38-83). Most patients were female (n = 11; 55%), Asian (n = 11; 55%), and had an ECOG performance status of 1 (n = 16; 80%). Thirteen (65%) patients had an an exon 19 deletion as opposed to an L858R mutation. Half of patients had brain metastases at baseline.

The median number of prior lines of therapy was 2 (range, 1-3). Prior therapy consisted of a first- or second-generation TKI (n = 9; 45%), osimertinib (Tagrisso; n = 14; 70%), and platinum-based chemotherapy (n = 5; 25%).

At a median follow-up of 7.1 months (range, 2.4-10.4), the median number of treatment cycles was 10 (range, 2-15). The median number of cycles of carboplatin and pemetrexed were 4 and 7.5, respectively.

Additional findings attested to the durability of the regimen, with a median DOR, PFS, and OS that were not estimable. Notably, 15 of 20 patients remain on treatment, including all 10 responders.

“Individual AEs were mostly low grade, and EGFR- and MET-related AEs [adverse effects] were consistent with previously reported data on amivantamab and lazertinib,” the study authors wrote.

EGFR-specific treatment-emergent AEs (TEAEs) included rash (any grade, 75%; grade ≥3, 5%), stomatitis (any grade, 60%; grade ≥3, 0%), paronychia (any grade, 50%; grade ≥3, 0%), dermatitis acneiform (any grade, 35%; grade ≥3, 10%), and diarrhea (any grade, 25%; grade ≥3, 5%). MET-specific TEAEs included hypoalbuminemia (any grade, 15%; grade ≥3, 5%).

Other reported TEAEs included neutropenia (any grade, 85%; grade ≥3, 70%), infusion related reaction (any grade, 60%; grade ≥3, 0%), fatigue (any grade, 50%; grade ≥3, 25%), nausea (any grade, 40%; grade ≥3, 0%), thrombocytopenia (any grade, 40%; grade ≥3, 25%), constipation (any grade, 35%; grade ≥3, 0%), decreased appetite (any grade, 35%; grade ≥3, 5%), anemia (any grade, 25%; grade ≥3, 5%), epistaxis (any grade, 25%; grade ≥3, 0%), hemorrhoids (any grade, 25%; grade ≥3, 0%), leukopenia (any grade, 25%; grade ≥3, 15%), dyspepsia (any grade, 20%; grade ≥3, 0%), insomnia (any grade, 20%; grade ≥3, 0%), pulmonary embolism (any grade, 20%; grade ≥3, 5%), vomiting (any grade, 20%; grade ≥3, 0%), weight decrease (any grade, 20%; grade ≥3, 0%), back pain (any grade, 15%; grade ≥3, 0%), COVID-19 (any grade, 15%; grade ≥3, 0%), dizziness (any grade, 15%; grade ≥3, 0%), hypomagnesemia (any grade, 15%; grade ≥3, 0%), hyponatremia (any grade, 15%; grade ≥3, 5%), paresthesia (any grade, 15%; grade ≥3, 0%), and peripheral edema (any grade, 15%; grade ≥3, 0%).

There were no cases of pneumonitis or interstitial lung disease. However, there was 1 fatality that was not attributed to any of the study drugs.

Investigators will further evaluate the quadruplet for patients with NSCLC in the ongoing phase 3 MARIPOSA study (NCT04988295) in patients who have received prior osimertinib. The combination of amivantamab and chemotherapy is being evaluated in NSCLC in the ongoing phase 3 PAPILLON study (NCT04538664) in patients with 

Marmarelis M, Lee SH, Spira AI, et al. Amivantamab and lazertinib in combination with platinum-based chemotherapy in relapsed/refractory 

-mutant NSCLC. Presented at: 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria; Abstract MA07.04.

Phase 1 findings showed a 50% overall response rate among patients with EGFR-mutated non–small cell lung cancer who received amivantamab in combination with lazertinib plus carboplatin and pemetrexed.

Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLC

Most patients travel to receive CAR T-cell therapy at a specialized center and clear communication with the primary care provider following treatment is key in ensuring appropriate follow-up care, says Sherry Adkins, MSN, ANP-C.

Adkins is a nurse practitioner in the Department of Myeloma and Lymphoma at University of Texas MD Anderson Cancer Center, who has been involved with several CAR T-cell therapy trials. She also serves as the supervisor for advanced practice providers administering CAR T-cell therapies at the institution.

®, Adkins discussed the significance of the 

recent FDA approval of lisocabtagene autoleucel

 (Breyanzi) in the second-line setting for patients with large B-cell lymphoma.

In the discussion, she highlights the value of communicating common effects to the primary care provider such as low blood counts following this therapy, and to give clear instructions on when the patient would require a transfusion for anemia or thrombocytopenia.

It is also important that the primary care provider be cognizant of the prophylactic antimicrobials that a patient should be taking following treatment, she added. At MD Anderson, Adkins notes that patients are treated with antiviral and anti-pneumocystis pneumonia prophylactically for 1 year to protect them against shingles, which was reported among patients who ended their prophylaxis early.

“It is important for the patient to know [this information as well],” Adkins adds, advising that patients keep a copy of their CAR T-cell therapy information on hand should a medical emergency arise. “If they ever need to go to the emergency department, they can present that to the emergency department to help [the care team] understand some things about [their] CAR T-cell therapy.”

Videos

Sherry Adkins, MSN, ANP-C, discusses some key considerations in ensuring quality patient care after they have completed CAR T-cell therapy at a specialized center.

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

Lindsay Fischer is the Associate Editor at ONN. She joined MJH life sciences in 2021 after graduating from Rutgers University with majors in both English and Spanish and a minor in creative writing. When she is not writing, or researching the latest oncology nursing news, Lindsay is an amateur backpacker and rollerblader. Email Lindsay at lfischer@mjhlifesciences.com

Fam-trastuzumab deruxtecan-nxki (Enhertu) has received accelerated approval from the FDA based on findings from DESTINY-Lung02 (NCT04644237). The antibody-drug conjugate has been approved for previously treated patients with 

-mutated unresectable or metastatic non–small cell lung cancer (NSCLC).

Phase 2 findings showed that the overall response rate among a pre-specified patient cohort (n = 52) was 57.7% (95% CI, 43.2%-71.3%), as confirmed by blinded independent central review. Complete responses were observed in 1.9% of patients and partial responses were observed in 55.8% of patients. The median duration of response was 8.7 months (95% CI 7.1-not estimable). Further analyses on DESTINY-Lung02 trial are anticipated at upcoming medical meetings.

“The approval of trastuzumab deruxtecan in NSCLC is an important milestone for patients and the oncology community,” Bob T. Li, MD, PhD, MPH, a medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center, said in a news release. “After 2 decades of research into the role of targeting 

 in lung cancer, the approval of the first HER2-directed treatment option validates 

 as an actionable target in lung cancer and marks an important step forward for treating this patient population with unmet medical needs.”

The recommended dose of trastuzumab deruxtecan is 5.4 mg/kg administered as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. For patients who require dose reduction because of adverse events (AEs), the first recommended dose reduction for NSCLC is 4.4 mg/kg, followed by 3.2 mg/kg. If a patient is unable to tolerate 3.2 mg/kg, treatment should be discontinued.

Trastuzumab deruxtecan should not be re-escalated following a dose reduction. If a patient misses a dose or has it delayed, the dose should be administered as soon as possible. Providers should not wait until the next planned cycle, but rather adjust the schedule so to maintain a 3-week interval between doses.

According to the label, the targeted therapy is moderately emetogenic, and may induce delayed nausea and/or vomiting. Prophylactic antiemetic medications are recommended and should be administered in accordance with institutional guidelines.

Trastuzumab deruxtecan is associated with the following clinically significant AEs: interstitial lung disease (ILD)/pneumonitis, neutropenia and left ventricular dysfunction.

-mutant NSCLC who received this agent at 5.4 mg/kg. The median onset time was 2.8 months (range, 1.2-21 months). Approximately 1% of patients died because of ILD complications.

Patients should be taught to report any cough, dyspnea, fever, or any new or worsening respiratory symptoms. Patients suspected of having ILD should be assessed via radiographic imaging. Consulting a pulmonologist may be appropriate.

For asymptomatic ILD, corticosteroid treatment may be considered, with a treatment hold until recover. In the event of grade 2 or higher ILD, systematic corticosteroid treatment should be initiated promptly, and continued for at least 14 days with a gradual taper across a minimum of 4 weeks. Patients diagnosed with symptomatic ILD must permanently discontinue trastuzumab deruxtecan.

Decreased neutrophil counts occurred in 65% of patients with NSCLC who received trastuzumab deruxtecan, of whom 16% had grade 3 or 4 severity. The median onset time was 22 days (range, 2-664 days). Approximately 1.1% of patients developed febrile neutropenia. Complete blood counts should be assessed at baseline and monitored after each dose. Depending on neutropenia severity, dose interruptions or reductions may be necessary.

Left ventricular dysfunction occurred in 3.6% of patients, of which 0.4% were grade 3. Left ventricular ejection fraction (LVEF) decreased has been observed with anti-HER2 therapies, including trastuzumab deruxtecan. LVEF should be assessed at baseline and at regular intervals throughout treatment. If LVEF drops below 40% or an absolute decrease from baseline greater than 20% is detected, the targeted therapy should be permanently discontinued. If symptomatic congestive heart failure occurs, the therapy should be discontinued.

As of August 2022, the agent has not been studied in patients with a history of clinically significant heart disease of LVEF less than 50% before treatment initiation.

Patients should also be educated about the embryo-fetal toxicity associated with the drug. Common AEs included in the trial included nausea (61%), decreased white blood cell count (60%), decreased hemoglobin (58%), decreased neutrophil count (52%), decreased lymphocyte count (43%), decreased platelet count (40%), decreased albumin (39%), increased aspartate aminotransferase (35%), increased alanine aminotransferase (34%), fatigue (32%), constipation (31%), decreased appetite (30%), vomiting (26%), increased alkaline phosphatase (22%), and alopecia (21%).

If not immediately used, trastuzumab deruxtecan should be protected from light and stored in a refrigerator between 36 to 46 degrees Fahrenheit. It should not be frozen. If not used after 24 hours, it should be discarded.

The reconstituted agent should be dilated in an intravenous infusion bag containing 100 mL of 5% dextrose injection, USP. It should not be diluted with sodium chloride injection, USP.

It is compatible with infusion bags composed of polyvinylchloride or polyolefin, filters used during administrations should also be composed of polyvinylchloride or polyolefin. The first infusion should be given over a 90-minute span. If well tolerated, further infusions can be given over a 30-minute span.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. FDA. Updated August 11, 2022. Accessed August 12, 2022. https://bit.ly/3bVts9g

Enhertu. Prescribing information. Daiichi Sankyo Company, Ltd; 2022. Accessed August 12, 2022. 

The FDA has approved trastuzumab deruxtecan for patients with HER2-mutated non–small cell lung cancer after the DESTINY-Lung02 results demonstrated a 57% overall response rate with the agent. The drug comes with warning for interstitial lung disease, neutropenia, and left ventricular dysfunction. 

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Following data from a 22-month extended follow-up, the FDA has granted capmatinib (Tabrecta) full approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a 

 exon 14 skipping, as detected by an FDA-approved test.

 on the same indication based on initial overall and duration of response (DOR) rates observed in the GEOMETRY mono-1 trial (NCT02414139), a multicenter, non-randomized, open-label, multi-cohort study. Patients with metastatic disease (n = 160) and a mutation leading to 

 exon skipping received 400 mg of oral capmatinib twice daily until disease progression or unacceptable toxicity.

Data supporting the 2020 accelerated approval included the overall response rate (ORR), which was 68% (95% CI, 55%-80%) among the treatment-naïve subgroup (n = 60) and 44% (95% CI, 34%-54%) in the pretreated group (n = 100). The DOR was 16.6 months (95% CI, 8.4-22.1) and 9.7 months (95% CI, 5.6-13), respectively.

The recommended dose for capmatinib is 400 mg orally twice daily with or without food. Patients should be instructed to swallow the tablets whole.

 They should not be broken, crushed, or chewed. If a patient misses or vomits a dose, they should not attempt to make up the dose, but instead wait and take the next dose at the scheduled time.

In the event of adverse reactions, providers should reduce the dose to 300 mg twice daily. At second adverse event (AE), the dose should be further reduced to 200 mg twice daily. Patients who are unable to tolerate 200 mg twice daily should permanently discontinue the drug.

The drug comes with warnings for interstitial lung disease (ILD) and pneumonitis, hepatotoxicity, and pancreatic toxicity. Patients should be educated for their increased risks of these events and taught to monitor and report the appropriate symptoms.

Approximately 4.8% of patients enrolled in GEOMETRY mon-1 experienced ILD or pneumonitis, and 1.9% of these cases were graded as grade 3. One patient died as a result of ILD/pneumonitis and 9 patients discontinued treatment because of ILD/pneumonitis complications.

Any signs of pulmonary symptoms, including dyspnea, cough, and fever should be monitored and reported immediately. The median time-to-onset time for grade 3 or worse events was 1.8 months (0.2 months – 1.7 years). Capmatinib should immediately be withheld if this AE is suspected and discontinued if it is positively identified.

An increased in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) was observed in 15% of patients who received capmatinib, of which 7% became grade 3 or 4. Three patients discontinued treatment because of hepatotoxicity.

Liver function should be tested at baseline and monitor every 2 weeks throughout the first months of treatment. These tests should include ALT, AST, and total bilirubin. After 3 months, la should be collected once a month, or as clinically indicated, with more frequent routine assessment for those who develop increased transaminases or bilirubin. If severe AEs begin to develop, it may be appropriate to withhold, dose reduce, or permanently discontinue capmatinib.

Fourteen patients experienced elevations in amylase and lipase levels, 7% and 1.9% of whom experienced grade 3 and 4 severity, respectively. Three patients discontinued because of pancreatic toxicity. One patient permanently discontinued treatment because of grade 3 pancreatitis.

Amylase and lipase levels should be assessed at baseline and regularly monitored throughout treatment. If severe AEs begin to develop, it may be appropriate to withhold, dose reduce, or permanently discontinue the agent.

Overall, the most common serious AEs included dyspnea (7%), pneumonia (7%), pleural effusion (4.3%), musculoskeletal pain (3.8%), general physical health deterioration (2.9%), ILD/pneumonitis (2.7%), and vomiting (2.4%). Fatal AEs occurred in 0.5% of treated patients, with pneumonitis representing the leading specified cause (0.3%).

Seventeen patients needed to discontinue because of an AE. The AEs most commonly associated with discontinuation included ILD/pneumonitis (2.4%), edema (2.4%), fatigue (1.3%), and pneumonia (1.1%).

Dose interruptions occurred in approximately 57% of patients on the trial. The AEs most likely to require a dose interruption included edema, increased blood creatinine, nausea, increased lipase, vomiting, increased ALT, dyspnea, pneumonia, fatigue, increased amylase, increased AST, musculoskeletal pain, abdominal pain, and increased blood bilirubin. The AEs most likely to require a dose reduction were edema, increased ALT, and increased blood creatinine.

According to a news release, nearly 70% of patients with NSCLC have a genomic mutation, and 3% to 4% of patients with NSCLC have 

The approval of this agent represents another targeted therapy for those 4000 to 5000 patients with this oncogenic driver mutation.

FDA approves capmatinib for metastatic non-small cell lung cancer. FDA. August 10, 2022. Accessed August 11, 2022. 

Capmatinib. Prescribing information. Novartis Pharmaceuticals Corp; 2022. Accessed August 11, 2022. https://bit.ly/3JLN2kQ

Novartis announces FDA approval of MET inhibitor Tabrecta for metastatic non-small cell lung cancer with METex14. May 6, 2020. Accessed August 11, 2022. https://bit.ly/2SIEmTc

The FDA has granted capmatinib regular approval for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation leading to MET exon 14 skipping. The drug comes with warning for pneumonitis, hepatotoxicity, and pancreatic toxicity. 

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

In an unprecedented age of health care burnout, hospital administrators may
need to think outside of the box to find ways to engage and support employees.

Structured Onboarding Processes Boost Employee Retention 

Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting. 

Approaches to Urothelial Care Call for Nuanced AE Management

A biologics license application for the IL-15 superagonist N-803 has been accepted and the agent will be reviewed for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer carcinoma in situ.

N-803 BLA Undergoes Review For BCG-Unresponsive Non–Muscle Invasive Bladder Cancer in Situ

In a presentation at the 6th Annual School of Nursing Oncology™, Laura Wood, RN, MSN, OCN, highlights key nurse takeaways with VEGF TKI/immune checkpoint inhibitor therapy for patients with renal cell carcinoma. 

Evolution of Frontline VEGF TKI/Immunotherapy Treatments Propels Field of Renal Cell Carcinoma

At the 6th Annual SONO meeting, Kelley A. Rone, DNP, RN, AGNP-C, reviewed evidence supporting molecular testing in patients with colorectal cancer. 

Molecular Profiling Is a Necessity in Colorectal Cancer Treatment 

Patients with previously treated non–small cell lung cancer experienced a median overall survival of 16.9 months with second- or third-line tislelizumab vs 11.9 months with docetaxel. 

Tislelizumab Maintains Superior Overall Survival Benefit Vs Docetaxel in Pretreated NSCLC

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor. 

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

Treatments options for various histologies of leukemia are expanding with FDA approvals for drugs such as the combination of ivosidenib/azacitidine and the CAR T-cell therapy brexucabtagene autoleucel.

Nurses Adapt to New Hematology Advances and Approvals in Leukemia Treatment  

Patients with hormone-sensitive prostate cancer who received darolutamide in combination with docetaxel experienced superior overall survival and time-to-pain progression benefit. 

FDA Approves Darolutamide Tablets for Select Patients With Prostate Cancer

The biologics license application for omidubicel has been granted priority review and will be assessed as a potential treatment for patients with blood cancer who require allogeneic hematopoietic stem cell transplant.

FDA OKs Omidubicel Priority Review For Patients in Need of Allogeneic HSCT

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.

FDA Schedules ODAC Meetings to Review Pending Drug Applications

Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.

Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC

The FDA has approved the first targeted therapy for patients with HER2-low metastatic breast cancer.

Trastuzumab Deruxtecan Is Approved for Patients With Metastatic HER2-Low Breast Cancer

Medical providers should strive to make all patients feel welcome and safe.

Addressing Disparities: Practicing Inclusion for LGBTQ+ Patients With Cancer

Sherry Adkins, MSN, ANP-C, discusses the significance of incorporating CAR T-cell therapy regimens, such as lisocabtagene autoleucel, into earlier lines of treatment for patients with relapsed/refractory large B-cell lymphoma.

Top Medical News

Larotrectinib Holds Ground as Effective Treatment in NTRK-Positive Lung Cancer

Amivantamab/Lazertinib/Chemo Regimen Gains Traction in EGFR-Mutant NSCLC

Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy

HER2-Directed Therapy, Trastuzumab Deruxtecan, Approved for Metastatic NSCLC

Capmatinib Snags Full FDA Approval for MET Exon 14 Skipping NSCLC

Most Recent